- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01052909
Bioequivalence Study of Dr.Reddy's Laboratories Limited, Glimepiride Tablets 1 mg Under Fasting Condition
19. januar 2010 opdateret af: Dr. Reddy's Laboratories Limited
Randomized, 2-way Crossover, Bioequivalence Study of Glimepiride 1 mg Tablets and Amaryl 1 mg Tablets in Healthy Subjects Under Fasting Condition
The purpose of this bioequivalence study is to compare a test Glimepiride 1 mg tablets of Dr.Reddy's Laboratories Limited versus reference Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc in healthy subjects, under fasting condition.
Studieoversigt
Detaljeret beskrivelse
The study was Single centre, randomized, single-dose, open-label,2-way crossover, bioequivalence study to compare a test Glimepiride 1 mg tablets of Dr.Reddy's Laboratories Limited versus Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc in healthy subjects, under fasting condition.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
44
Fase
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Quebec
-
Sainte-Foy, Quebec, Canada, GIV 2KB
- Anapharm Inc
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Male or non-child-bearing potential female,smoker and or non-smoker,18 years of age and older.
- Capable of consent.
- Non-child-bearing potential female subject:
- Post-menopausal state:absence of menses for 12 months prior to drug. administration or hysterectomy with bilateral oophorectomy at least 6 months prior to drug administration.
- Surgically sterile: hysterectomy, bilateral oophorectomy, or tubal ligation at least 6 months prior to drug administration.
Exclusion Criteria:
Subjects to whom any of the following applies will be excluded from the study:
- Clinically significant illnesses & surgery within 4 weeks prior to the administration of the study medication.
- Any clinically significant abnormality found during medical screening.
- Any reason which,in the opinion of the Medical Sub-Investigator,would prevent the subject from participating in the study.
- Abnormal laboratory tests judged clinically significant.
- Positive testing for hepatitis B and C or HIV at screening.
- ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
- BMI≥30.0.
- History of significant alcohol abuse within six months prior to the screening visit or any indication of the regular use of more than fourteen units of alcohol per week (l Unit=150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol).
- History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine [PCP] and crack) within 1 year prior to the screening visit or positive urine drug screen at screening.
- History of allergic reactions to glimepiride or other sulfonylureas (e.g. chlopropamide,gliclazide, tolbutamide and glyburide).
- History of allergic reactions to heparin.
- Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampinlrifabutin; examples of inhibitors: antidepressants, cimetidine. diltiazem, erythromycin, ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine) within 30 days prior to administration of the study medication.
- Use of an investigational drug or participation in an investigational study within 30 days prior to administration of the study medication. .
- Clinically significant history or presence of any clinically significant gastrointestinal pathology (e.g. chronic diarrhea. inflammatory bowel diseases), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism. or excretion of the drug.
- Any clinically significant history or presence of clinically significant neurological,endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or metabolic disease.
- Use of prescription medication (including hormone therapy) within 14 days prior to administration of study medication or over-the-counter products (including natural food supplements, vitamins, garlic as a supplement) within 7 days prior to administration of study medication, except for topical products without systemic absorption.
- Difficulty to swallow study medication.
- Smoking more than 25 cigarettes per day.
- Any food allergy, intolerance, restriction or special diet that could, in the opinion of the Medical Sub-Investigator. contraindicate the subject's participation in this study.
- A depot injection or an implant of any drug within 3 months prior to administration of study medication.
- Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or loss of whole blood prior to administration of the study medication as follows:
- 50 mL to 300 mL of whole blood within 30 days,
- 301 mL to 500 mL of whole blood within 45 days, or
- more than 500 mL of whole blood within 56 days prior to drug administration.
- Subjects with diabetes (including diabetes mellitus).
- Subjects with known serious hepatic impairments.
- Subjects with clinically significant presence or history of hypoglycemia.
Additional exclusion criteria for females only:
- Breast-feeding subject.
- Positive urine pregnancy test at screening
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Glimepiride
Glimepiride tablets 1 mg of Dr. Reddy's Laboratories Limited
|
Glimepiride tablets 1 mg
Andre navne:
|
Aktiv komparator: Amaryl
Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc
|
Glimepiride tablets 1 mg
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Bioequivalence study of Dr. Reddy's Laboratories Limited, Glimepiride tablets 1 mg under Fasting condition
Tidsramme: 4 months
|
4 months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. december 2003
Primær færdiggørelse (Faktiske)
1. december 2003
Studieafslutning (Faktiske)
1. december 2003
Datoer for studieregistrering
Først indsendt
19. januar 2010
Først indsendt, der opfyldte QC-kriterier
19. januar 2010
Først opslået (Skøn)
21. januar 2010
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
21. januar 2010
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
19. januar 2010
Sidst verificeret
1. januar 2010
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 30286
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Glimepiride
-
Dong-A ST Co., Ltd.AfsluttetType 2 diabetesKorea, Republikken
-
GlaxoSmithKlineAfsluttetDiabetes mellitus, type 2Korea, Republikken, Malaysia, Filippinerne, Thailand, Den Russiske Føderation, Mexico
-
IKFE Institute for Clinical Research and DevelopmentAfsluttetType 2 diabetes mellitus | Insulin resistensTyskland
-
Laboratorios Silanes S.A. de C.V.AfsluttetType 2 diabetes mellitusMexico
-
Laboratorios Silanes S.A. de C.V.Rekruttering
-
SanofiAfsluttet
-
LG Life SciencesUkendt
-
Kyunghee University Medical CenterSanofi; Korea University Guro Hospital; Hanyang University; The Catholic University... og andre samarbejdspartnereAfsluttetType 2 diabetes mellitus | Pancreas betacelle funktion | GlukotoksicitetKorea, Republikken
-
LG Life SciencesAfsluttetSund og raskKorea, Republikken